Alkermes FY2026 EPS Forecast Reduced by HC Wainwright

Alkermes plc (NASDAQ:ALKS) – Equities researchers at HC Wainwright cut their FY2026 EPS estimates for Alkermes in a research report issued on Monday, May 18th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.44) for the year, down from their previous forecast of ($0.41). HC Wainwright has a “Neutral” rating and a $43.00 price objective on the stock. The consensus estimate for Alkermes’ current full-year earnings is ($0.42) per share.

Several other analysts also recently issued reports on the stock. Truist Financial raised shares of Alkermes to a “strong-buy” rating in a research note on Wednesday, March 25th. Royal Bank Of Canada decreased their price target on shares of Alkermes from $47.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Weiss Ratings downgraded shares of Alkermes from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Wells Fargo & Company lifted their price target on shares of Alkermes from $43.00 to $44.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, Zacks Research raised shares of Alkermes from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $45.40.

Alkermes Stock Down 0.5%

Shares of NASDAQ ALKS opened at $37.00 on Wednesday. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.27 and a quick ratio of 1.70. The company has a market cap of $6.17 billion, a P/E ratio of 41.11 and a beta of 0.31. Alkermes has a 1 year low of $25.17 and a 1 year high of $39.56. The firm has a 50-day simple moving average of $32.83 and a two-hundred day simple moving average of $31.41.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Saturday, February 14th. The company reported $0.29 earnings per share (EPS) for the quarter. The business had revenue of $384.55 million during the quarter. Alkermes had a net margin of 9.78% and a return on equity of 9.26%.

Insider Activity

In other news, SVP Christian Todd Nichols sold 6,000 shares of Alkermes stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $30.00, for a total transaction of $180,000.00. Following the completion of the sale, the senior vice president owned 109,769 shares of the company’s stock, valued at approximately $3,293,070. The trade was a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $33.40, for a total transaction of $300,600.00. Following the completion of the transaction, the executive vice president directly owned 81,389 shares of the company’s stock, valued at $2,718,392.60. This trade represents a 9.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 39,102 shares of company stock valued at $1,265,090. Corporate insiders own 4.59% of the company’s stock.

Hedge Funds Weigh In On Alkermes

A number of large investors have recently bought and sold shares of ALKS. Assetmark Inc. raised its stake in Alkermes by 933.8% in the third quarter. Assetmark Inc. now owns 827 shares of the company’s stock worth $25,000 after buying an additional 747 shares in the last quarter. Cullen Frost Bankers Inc. bought a new position in Alkermes in the fourth quarter worth approximately $28,000. Johnson Financial Group Inc. bought a new position in Alkermes in the third quarter worth approximately $31,000. UMB Bank n.a. raised its stake in Alkermes by 57.6% in the fourth quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock worth $34,000 after buying an additional 446 shares in the last quarter. Finally, Salomon & Ludwin LLC raised its stake in Alkermes by 115.6% in the fourth quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock worth $35,000 after buying an additional 667 shares in the last quarter. Institutional investors own 95.21% of the company’s stock.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.